Healthcare / Medical Instruments & SuppliesShanghai
$17.08
-0.10 (-0.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $38.7M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
48.8x
↑EV/EBITDA
26.7x
↑ROE
7.5%
↑Gross Margin
44.7%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.3%
FCF CAGR
—
FCF margin
21.7%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $447.4M · net income $64.9M · FCF $97.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $447.4M | $447.4M | $274.9M | $480.2M | $383.5M |
| Net Income | $64.9M | $64.9M | $-20.0M | $99.8M | $67.0M |
| EBITDA | $97.3M | $97.3M | $3.2M | $157.0M | $103.6M |
| EPS | 0.40 | 0.40 | -0.12 | 0.60 | 0.41 |
| Gross Margin | 44.7% | 44.7% | 43.9% | 51.3% | 50.5% |
| Operating Margin | 12.5% | 12.5% | -8.5% | 25.6% | 20.3% |
| Net Margin | 14.5% | 14.5% | -7.3% | 20.8% | 17.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.00 | 0.00 |
| Current Ratio | 2.91 | 2.91 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $97.3M | $97.3M | $-29.5M | $38.7M | $-38.4M |
| Returns | |||||
| ROE | 7.5% | 7.5% | -2.5% | 11.2% | 8.2% |
| Valuation | |||||
| P/E | 48.80 | 48.80 | — | 49.52 | 43.18 |
| EV/EBITDA | 26.74 | 26.74 | 494.73 | 29.66 | 25.78 |
| P/B | 3.22 | 3.22 | 2.06 | 5.53 | 3.53 |
| Growth & Yield | |||||
| Revenue Growth | 62.8% | 62.8% | -42.8% | 25.2% | — |
| EPS Growth | 433.3% | 433.3% | -120.0% | 47.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.9%
EPS terminal req.
$1.52
Spread vs growth
377.4%
5Y implied EPS CAGR
35.6%
EPS terminal req.
$1.83
Spread vs growth
397.7%
10Y implied EPS CAGR
22.1%
EPS terminal req.
$2.95
Spread vs growth
411.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+30.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → 0.40
Residual
+30.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.